Mainz Biomed NV (NASDAQ:MYNZ) shares are trading lower by 46% to $1.21 during Monday’s session has entered a securities purchase agreement with institutional investors to raise $5 million through a registered direct offering.
The agreement involves the sale of ordinary shares (or pre-funded warrants) and warrants, with an effective purchase price of $1.20 per share.
The offering, managed by Titan Partners Group, a division of American Capital Partners, is set to close around November 15, contingent upon meeting customary closing conditions.
See Also: What’s Going On With Plug Power Stock?
According to data from Benzinga Pro, MYNZ has a 52-week high of $9.61 and a 52-week low of $1.16.
